These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 19793700)

  • 1. Update on identifying and managing osteoporosis in women with breast cancer.
    Yamamoto DS; Viale PH
    Clin J Oncol Nurs; 2009 Oct; 13(5):E18-29. PubMed ID: 19793700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis.
    Hadji P
    Crit Rev Oncol Hematol; 2009 Jan; 69(1):73-82. PubMed ID: 18757208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating bone health in women with oestrogen receptor positive breast cancer (ERBC) starting aromatase inhibitors.
    Clunie GP; Clark A; Mortimer CJ; Stephenson S; Aitken J; Smith C; Sherwin E; Archer TJ
    Eur J Surg Oncol; 2009 May; 35(5):475-80. PubMed ID: 18950981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of osteoporosis after breast cancer.
    Reid DM
    Maturitas; 2009 Sep; 64(1):4-8. PubMed ID: 19709826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.
    Reid DM; Doughty J; Eastell R; Heys SD; Howell A; McCloskey EV; Powles T; Selby P; Coleman RE
    Cancer Treat Rev; 2008; 34 Suppl 1():S3-18. PubMed ID: 18515009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors.
    Mincey BA; Duh MS; Thomas SK; Moyneur E; Marynchencko M; Boyce SP; Mallett D; Perez EA
    Clin Breast Cancer; 2006 Jun; 7(2):127-32. PubMed ID: 16800971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The causes and treatment of bone loss associated with carcinoma of the breast.
    Lester J; Dodwell D; McCloskey E; Coleman R
    Cancer Treat Rev; 2005 Apr; 31(2):115-42. PubMed ID: 15847981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aromatase inhibitors and mammographic breast density in postmenopausal women receiving hormone therapy.
    Mousa NA; Crystal P; Wolfman WL; Bedaiwy MA; Casper RF
    Menopause; 2008; 15(5):875-84. PubMed ID: 18480735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse bone effects during pharmacological breast cancer therapy.
    Bjarnason NH; Hitz M; Jorgensen NR; Vestergaard P
    Acta Oncol; 2008; 47(4):747-54. PubMed ID: 18465344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of bone loss associated with breast cancer: a review].
    Shao J; Gong YP
    Ai Zheng; 2008 Feb; 27(2):218-22. PubMed ID: 18279626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer treatment-induced bone loss in breast and prostate cancer.
    Saad F; Adachi JD; Brown JP; Canning LA; Gelmon KA; Josse RG; Pritchard KI
    J Clin Oncol; 2008 Nov; 26(33):5465-76. PubMed ID: 18955443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone mineral density and bone turnover in postmenopausal women treated for breast cancer.
    Waltman NL; Ott CD; Twiss JJ; Gross GJ; Lindsey AM; Moore TE
    Cancer Nurs; 2008; 31(3):182-90. PubMed ID: 18453874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reducing the risk of bone loss associated with breast cancer treatment.
    Hadji P
    Breast; 2007 Dec; 16 Suppl 3():S10-5. PubMed ID: 18023583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant aromatase inhibitors and bone health.
    Chowdhury S; Pickering LM; Ellis PA
    J Br Menopause Soc; 2006 Sep; 12(3):97-103. PubMed ID: 16953982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risks of osteoporosis associated with breast cancer treatment: the need to access to preventive treatment.
    Rozenberg S; Carly B; Liebens F; Antoine C
    Maturitas; 2009 Sep; 64(1):1-3. PubMed ID: 19709824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies.
    Coleman RE; Body JJ; Gralow JR; Lipton A
    Cancer Treat Rev; 2008; 34 Suppl 1():S31-42. PubMed ID: 18486346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer treatment-induced bone loss.
    Adler RA
    Curr Opin Endocrinol Diabetes Obes; 2007 Dec; 14(6):442-5. PubMed ID: 17982349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of secondary causes of bone loss among breast cancer patients with osteopenia and osteoporosis.
    Camacho PM; Dayal AS; Diaz JL; Nabhan FA; Agarwal M; Norton JG; Robinson PA; Albain KS
    J Clin Oncol; 2008 Nov; 26(33):5380-5. PubMed ID: 18955450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aromatase inhibitors and bone health.
    Bundred NJ
    Curr Opin Obstet Gynecol; 2009 Feb; 21(1):60-7. PubMed ID: 19125005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risks and benefits of therapy with menopausal hormones versus selective estrogen-receptor modulators in peri- and postmenopausal women at increased breast cancer risk.
    Col NF; Chlebowski RT
    Menopause; 2008; 15(4 Suppl):804-9. PubMed ID: 18596602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.